Breaking News Instant updates and real-time market news.

SHPG

Shire

$185.79

-1.91 (-1.02%)

05:16
10/18/16
10/18
05:16
10/18/16
05:16

Shire granted EU Marketing Authorization of Onivyde in combination with 5-FU, LV

Shire announced that the European Commission has granted Marketing Authorization of Onivyde, also known as nal-IRI or MM-398, for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil, or 5-FU, and leucovorin, or LV, in adult patients who have progressed following gemcitabine-based therapy. ONIVYDE is the first and only approved treatment option for this patient population.

  • 26

    Oct

SHPG Shire
$185.79

-1.91 (-1.02%)

08/03/16
LEER
08/03/16
NO CHANGE
Target $231
LEER
Outperform
Shire price target raised to $231 from $213 at Leerink
Leerink analyst Jason Gerberry raised his price target for Shire to $231 from $213 on valuation after the company reported "solid" Q2 results. The analyst reiterates an Outperform rating on the shares.
08/31/16
JEFF
08/31/16
NO CHANGE
Target $262
JEFF
Buy
Shire making right moves in dry eye market, says Jefferies
After hosting meetings with management, Jefferies analyst David Steinberg believes Shire (SHPG) is making "all the right moves" to make its dry eye drug Xiidra a potential $2B peak product in the U.S. Shire's Xiidra is competing with Allergan's (AGN) $1.4B dry eye drug Restasis, Steinberg tells investors in a research note. The analyst does not think Shire will have any problem exceeding the drug's consensus sales forecast of $200M for next year. He keeps a Buy rating on the shares with a $262 price target.
09/26/16
HSBC
09/26/16
DOWNGRADE
HSBC
Hold
Shire downgraded to Hold from Buy at HSBC
HSBC analyst Steve McGarry downgraded SHire to Hold saying valuation is no longer compelling.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.